Annexon

Annexon Biosciences, based in South San Francisco, CA, is a biotechnology company that is dedicated to developing innovative therapies for complement-driven diseases. Led by a team of experienced scientists and researchers, Annexon focuses on targeting C1q, the initiating molecule of the classical complement pathway, to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases affecting the body, brain, and eye.

With a strong emphasis on scientific research and development, Annexon is committed to unlocking the next generation of complement therapies. Their pipeline consists of early complement inhibitors that aim to address a wide range of diseases in the body, brain, and eye. Passionate about delivering transformative therapies, Annexon is dedicated to improving the lives of individuals suffering from complement-driven diseases.

Generated from the website